Director's Dealing • Sep 12, 2024
Director's Dealing
Open in ViewerOpens in native device viewer
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B.
| 1. | Details of the person discharging managerial responsibilities/person closely associated | |
|---|---|---|
| a) | Name | Anne Breum |
| 2. | Reason for the notification | |
| a) | Position/status | Employee-elected member of the Board of Directors |
| b) | Initial notifica- tion/Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auc- tion monitor |
|
| a) | Name | Novozymes A/S, part of Novonesis Group |
| b) | LEI | 529900T6WNZXD2R3JW38 |
| 4. | conducted | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been |
| a) | Description of the financial instrument, type of instrument |
B-shares |
| Identification code | DK0060336014 | |
| b) | Nature of the transaction | Exercise of share options (purchase) from incentive program |
| c) | Price(s) and volume(s) | Volume Price 134 273.60 |
| d) | Aggregated information - Aggregated volume - Price |
134 36,662.40 |
| e) | Date of the transaction | September 11, 2024 |
| f) | Place of the transaction | Off exchange |
Company announcement No. 36
Tobias Bjorklund +45 3077 8682 [email protected]
Anders Enevoldsen +45 5350 1453 [email protected]
Novonesis is a global leading biosolutions company transforming the way we all produce, consume and live. In more than 30 industries our biosolutions are helping companies meet their business needs and the needs of our planet. Our 10,000 people worldwide work closely with our partners and customers to challenge conventional thinking and transform business with biology.
CVR number: 10 00 71 27 – LEI: 529900T6WNZXD2R3JW38
Novozymes A/S, part of Novonesis Group Krogshoejvej 36 2880 Bagsvaerd Denmark

| 1. | Details of the person discharging managerial responsibilities/person closely associated | ||
|---|---|---|---|
| a) | Name | Anne Breum | |
| 2. | Reason for the notification | ||
| a) | Position/status | Employee-elected member of the Board of Directors | |
| b) | Initial notifica- tion/Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auc- tion monitor |
||
| a) | Name | Novozymes A/S, part of Novonesis Group | |
| b) | LEI | 529900T6WNZXD2R3JW38 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
| a) | Description of the financial instrument, type of instrument |
B-shares | |
| Identification code | DK0060336014 | ||
| b) | Nature of the transaction | Sale of shares | |
| c) | Price(s) and volume(s) | Volume Price 36 468.50 39 468.50 56 468.50 |
|
| d) | Aggregated information - Aggregated volume - Price |
134 62,779.00 |
|
| e) | Date of the transaction | September 11, 2024 | |
| f) | Place of the transaction | Off exchange |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.